Astellas Signs a License Agreement with ExCellThera for In Vitro Use of UM171 in Pluripotent Stem Cells

Shots:

• ExCellThera to receive up front, future contingent payments along with manufacturing and supply fees for the licensed molecules
• The collaboration validates the immense clinical and commercial potential of UM171 in additional fields of development
• The collaboration allows the ExcelThera to focus on clinical programs and commercial plans for ECT-001 cell therapy product along with cell expansion and rejuvenation platform & other pre/clinical areas of interest

Click here to read full press release/ article | Ref: Globe Newswire | Image: HRI Portal